Yi Larson
Director/Board Member chez OLEMA PHARMACEUTICALS, INC.
Fortune : - $ au 31/03/2024
Profil
Mme Yi Larson est une directrice indépendante chez Olema Pharmaceuticals, Inc. Elle siège au conseil d'administration d'Olema Pharmaceuticals, Inc. et de Rayzebio, Inc. Mme Larson était auparavant employée en tant que directrice financière et vice-présidente exécutive par Turning Point Therapeutics, Inc. Elle a obtenu son diplôme de premier cycle à la Wharton School de l'Université de Pennsylvanie, un diplôme d'études supérieures au Massachusetts Institute of Technology et un MBA à la Wharton School de l'Université de Pennsylvanie.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
LIANBIO
-.--% | 10/04/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
16/06/2023 | 0 ( -.--% ) | - $ | 31/03/2024 |
Postes actifs de Yi Larson
Sociétés | Poste | Début |
---|---|---|
OLEMA PHARMACEUTICALS, INC. | Director/Board Member | 06/04/2021 |
Anciens postes connus de Yi Larson
Sociétés | Poste | Fin |
---|---|---|
RAYZEBIO, INC. | Director/Board Member | 26/02/2024 |
LIANBIO | Director of Finance/CFO | 19/12/2023 |
TURG POIN | Director of Finance/CFO | 31/03/2021 |
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Financial ConglomeratesFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Corporate Officer/Principal | - |
Formation de Yi Larson
Massachusetts Institute of Technology | Graduate Degree |
The Wharton School of the University of Pennsylvania | Masters Business Admin |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 3 |
---|---|
OLEMA PHARMACEUTICALS, INC. | Health Technology |
RAYZEBIO, INC. | Health Technology |
LIANBIO | Health Technology |
Entreprise privées | 2 |
---|---|
Turning Point Therapeutics, Inc.
Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
Goldman Sachs & Co. LLC
Goldman Sachs & Co. LLC Financial ConglomeratesFinance Goldman Sachs & Co. LLC (GS&Co.) is a securities brokerage firm headquartered in New York City. Founded in 1927, the firm is a subsidiary of The Goldman Sachs Group, Inc. (NYSE: GS). GS&Co. provides services to help hedge funds manage risk, monitor portfolios, maintain liquidity and build their businesses. They offer clients access to global equity and derivatives markets, as well as foreign exchange, commodities, European Lefts, rates and credit across the Americas, Europe and Asia. The firm proactively monitors capital markets, searching for pockets of liquidity and news that may require changes to those strategies. Integration with the Goldman Sachs network gives clients access to the firm's sectored block trades and their insights into price discovery. Their electronic trading program provides clients with tools to manage their trades from pre-trade analytics to post-trade analysis. | Finance |